Mavacamten — a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy

Authors: Piotr Pysz, Renata Rajtar-Salwa, Grzegorz Smolka, Iacopo Olivotto, Wojciech Wojakowski, Paweł Petkow-Dimitrow

Article type: Review
Received: March 26, 2021
Accepted: July 8, 2021
Published online: July 9, 2021

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Mavacamten — a new disease-specific option for pharmacological treatment of symptomatic patients with hypertrophic cardiomyopathy

Piotr Pysz1*, Renata Rajtar-Salwa2*, Grzegorz Smolka1, Iacopo Olivotto3, Wojciech Wojakowski1, Paweł Petkow-Dimitrow2

1Division of Cardiology and Structural Heart Diseases, Medical University of Silesia, Katowice, Poland
2Department of Cardiology and Cardiovascular Interventions, University Hospital, Kraków, Poland
3Cardiomyopathy Unit, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
*Both authors equally contributed to the study.

Short title: Mavacamten in treatment of hypertrophic cardiomyopathy

Conflicts of interest: IO: grants, research funding: Myokardia, Cytokinetics, Amicus, Shire Takeda, Sanofi Genzyme, Bayer, Menarini International, Boston Scientific. Advisory board/speakers' fees: Myokardia, Cytokinetics, Amicus, Shire Takeda, Sanofi Genzyme. WW: Advisory board Myokardia

Correspondence to:
Paweł Petkow Dimitrow,
2nd Department of Cardiology, Jagiellonian University Medical College,
Jakubowskiego 2, 30–688 Kraków, Poland,
phone: +48 12 400 22 50,
e-mail: dimitrow@mp.pl

ABSTRACT

Current pharmacotherapy for hypertrophic cardiomyopathy (HCM) is not disease-specific and has suboptimal efficacy, often necessitating interventional treatment. EXPLORER-HCM was a phase 3, randomized, double-blind, placebo-controlled multicenter clinical trial investigating effects of mavacamten, a first-in-class selective cardiac myosin inhibitor, in patients with HCM, left ventricular outflow obstruction (LVOTO) and New York Heart Association (NYHA) class II or III symptoms. The primary end-point was defined as either a ≥1.5 ml/kg/min increase in peak oxygen consumption (pVO2) and ≥1 NYHA class reduction or a ≥3.0 ml/kg/min pVO2
increase without NYHA class worsening. Secondary end-points evaluated changes in post-
exercise LVOT gradient, pVO₂, NYHA class, Kansas City Cardiomyopathy Questionnaire-
Clinical Summary Score (KCCQ-CSS), and Hypertrophic Cardiomyopathy Symptom
Questionnaire Shortness-of-Breath subscore (HCMSQ-SoB). A total of 251 patients were
randomized to receiving mavacamten or placebo. The primary and all secondary end-points
were met significantly more frequently in the mavacamten arm versus placebo. The safety
profile of mavacamten was similar to that of placebo. In conclusion, disease-specific treatment
with mavacamten in patients with obstructive HCM led to reduced LVOTO and improvement
in both objective functional parameters and patient-related health status.

Key words: hypertrophic cardiomyopathy, left ventricular outflow obstruction, mavacamten

INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy, with a
1:500 prevalence in the general population [1]. The diagnosis of HCM is based on
demonstrating significant thickening of at least one myocardial segment of the left ventricle.
Regardless of the imaging technique (echocardiography, magnetic resonance, computed
tomography), a cut-off value of 15 mm in diastole has been adopted. Additionally, in first-
degree relatives of patients with confirmed HCM, a wall thickness of ≥13 mm is deemed
sufficient for diagnosis. The core pathomechanism of HCM is represented by the enhanced
affinity between actin and myosin filaments leading to hypercontractility, left ventricular
diastolic dysfunction, and in about 70% of patients, dynamic left ventricular outflow tract
obstruction (LVOTO). So far, roughly 1500 mutations of about 11 genes encoding different
proteins of the sarcomere were identified. Most frequently (>70%), those responsible for
encoding the beta-myosin heavy chain-7 and myosin-binding C3 proteins are affected. Recent
investigations in understudied populations offer local and global verification of the genetic
mutation of HCM [2, 3]. The key features of HCM are unexplained wall thickening, abnormal
relaxation with increased filling pressures, myocardial fibrosis. Clinical manifestations are
heart failure (HF), atrial fibrillation (AF), ventricular arrhythmia, potentially leading to sudden
cardiac death, syncope, and angina. HCM can have a nonobstructive (no-HCM) or more
frequent obstructive (oHCM) form. Dynamic LVOTO related to systolic anterior motion
(SAM) of the mitral valve can be present at rest or detected after proper physiological
provocative test, i.e., exercise, especially in the upright position [4–7] in up to 70% cases (sum
of resting obstructive and provoked obstructive gradients) [8, 9]. Medical treatment of the HCM
with severe LVOTO (gradient of ≥50 mm Hg) has been challenging, with many patients experiencing poor quality of life and often drug side effects. As the disease-specific treatment for HCM is still lacking, the current therapeutic regimens are based on empiric use of drugs such as beta-blockers (BB), verapamil, or disopyramide. The medical therapy is effective, however often associated with drug side effects, in particular in the case of disopyramide. Patients with symptoms refractory to medical therapy usually require septal reduction therapies (SRT) which remains the most effective treatment provided it is performed in experienced high-volume centers.

**UNMET CLINICAL NEEDS IN OHCM WITH LVOTO**

Based on the 2014 European Society of Cardiology (ESC) guidelines, pharmacotherapy aiming to relieve the LVOTO and improve symptoms, encompasses BB, non-dihydropyridine calcium channel blockers (CCB) and disopyramide (unavailable in Poland). Similar medical management is recommended in recent American Heart Association/American College of Cardiology guidelines [10–12]. Such therapies often lead to a reduction of LVOT gradient and improvement of symptoms. Still, they are often associated with the clinically significant side effects, especially if combination therapy is used (BB or CCB + disopyramide). Also, the use of CCB in patients with HF and very high LVOT gradients is problematic due to their vasodilatory effects.

In the presence of LVOTO, beta-blockers became first-line pharmacotherapy [13, 14] over verapamil, reducing LVOT gradient via a negative inotropic effect. Direct comparison between propranolol and verapamil revealed that propranolol was more effective in gradient reduction, but only verapamil was able to significantly decrease New York Heart Association (NYHA) class [15]. Verapamil utility in oHCM with high resting gradients is limited by its vasodilating effects that can, infrequently, worsen gradient and symptoms [16, 17]. As such, we tend to avoid it in patients with high gradients and severe HF symptoms [16].

In the European HCM center of excellence [13, 14] nadolol is the first choice drug, considering its good tolerability, favorable electrophysiological profile, the potent effect on gradients, and adequate 24-h coverage. Conversely, in the American HCM center of expertise [16] bisoprolol is the BB of the first choice due to the highest beta-1 selectivity. However, in high doses of BB needed for obstruction, relief might be poorly tolerated (hypotension, bradycardia, decreased atrio-ventricular conduction, chronotropic incompetence, exacerbation of the chronic obstructive pulmonary disease, or erectile dysfunction). In comparison between BB and verapamil, only the latter improved coronary endothelial dysfunction [18]. Overall, the efficacy
and side effect profile of current pharmacotherapy is not optimal. Established SRT involve surgical septal myectomy (Morrow's operation) and transcatheter alcohol septal ablation. The first one is recommended in younger, active patients with thicker interventricular septum (IVS), higher LVOT gradient, and concurrent structural heart disease warranting, e.g., simultaneous mitral valve repair or replacement. Alternatively, the percutaneous approach is considered more suitable in the elderly, with IVS thickness below 18 mm. SRT effectively reduces symptoms in the majority (>95% myectomy and >75% alcohol septal ablation) of patients, however, must be performed in experienced high-volume centers and are not widely available.

All of the above are not targeting the underlying pathophysiology of the disease. The contractile apparatus is a promising target for novel drug development; therefore, investigation for new drug reducing LVOT gradient was crucial. In 2016 [19], a small-molecule allosteric inhibitor of myosin was discovered (initially coded MYK-461), currently named mavacamten. In contrast to non-specific inotropic negative drugs, mavacamten is a specific compound targeting the primary molecular defect of the cardiomyocyte's function [20–22].

**MECHANISM OF ACTION**

From the pathophysiological point of view, both oHCM and noHCM are characterized by hypercontractile left ventricular myocardium, despite hypertrophy status. The molecular underpinnings of hypercontractility relate to an energetically inefficient myosin. Active myosin is a composite of two myosin heads with intertwined tails. During the myosin force production cycle, there is an autoinhibited state, sometimes referred to as a super-relaxed state. With certain myosin mutations, the HCM sarcomere, this inhibited state is shortened, leading to hyperactivation and excess ATP utilization [23–25]. Mavacamten, a first-in-class oral small molecule, targets this process directly as an allosteric modulator of cardiac β-myosin, causing reversible inhibition of actin-myosin cross bridging (Figure 1). In detail, mavacamten stabilizes this inhibited state, effectively lengthening the time that myosin is inactive [23–25]. Mavacamten binds to myosin, stabilizes the super-relaxed conformation, and shifts the kinetics of the actin-activated phosphate release step of myosin activation, thus decreasing ATPase activity and essentially slowing myosin's interaction with actin. Although there are multiple myosin forms, Mavacamten is specific for β-myosin heavy chain, expressed in cardiac muscle. Mavacamten demonstrated low clearance, a high volume of distribution, long terminal elimination half-life, and high bioavailability after oral intake cross-species. Simple four-species allometric scaling led to predicted plasma clearance, the volume of distribution, and
half-life of 0.51 ml/min/kg; 9.5 l/kg, and 9 days, respectively, in humans [26]. Importantly this molecule is cardiac-selective and does not influence the function of skeletal muscles.

STUDIES IN ANIMAL MODELS
Green et al. [19] demonstrated that chronic administration of MYK-461 during development suppresses the development of ventricular hypertrophy, cardiomyocyte disarray, myocardial fibrosis and attenuates hypertrophic and profibrotic gene expression in mice model of HCM. In the echocardiographic study in the feline genetic model of oHCM, treatment with mavacamten reduced contractility eliminated SAM, and relieved LVOTO [27]. The latest study assessed the effect of mavacamten on cardiac muscle contraction in two transgenic mouse lines expressing the human isoform of cardiac myosin regulatory light chain in their hearts [28]. Findings indicate that the drug reduces isometric tension and Ca\(^{2+}\)-sensitivity of contraction via decreased strong cross-bridge binding.

FIRST IN MAN STUDIES
In the first study in patients, mavacamten was evaluated in a subgroup of oHCM in the open-label PIONEER-HCM (Pilot Study Evaluating drug in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) [29]. PIONEER-HCM was a prospective, phase 2 study to evaluate the pharmacokinetics and pharmacodynamics of mavacamten. The inclusion criteria were resting LVOT gradient greater than 30 or provoked gradient greater than 50 mm Hg. The study included 21 patients. In subgroup A (n = 11), higher-dose mavacamten resulted in a significant and rapid reduction in the degree of post-exercise LVOTO (average ∼90 mm Hg decrease in post-exercise LVOT gradient. In this subgroup, there was also a substantial (17%) improvement in exercise capacity [peak oxygen consumption (VO\(_2\)) + 3.5 ml/kg/min]. Subgroup B (n = 10) received lower doses of mavacamten. While improvement in LVOT obstruction (average ∼25 mm Hg decrease in post-exercise LVOT gradient) and exertional capacity (peak VO\(_2\) + 1.7 ml/kg/min) were more modest, there was still significant symptoms improvement. In both higher and lower doses of mavacamten, a substantial reduction in gradient was observed. Furthermore, eight participants had a decrease of LVOT gradient <30 mm Hg. Apart from positive hemodynamic changes, a beneficial lowering of serum N-terminal pro-brain natriuretic peptide (NT-proBNP) was also observed (biomarker representing myocardial wall stress). Importantly, the left ventricular ejection fraction declined by 6% to 15%, which corresponds with the expected mode of cellular action of the myosin inactivator. These positive findings set the stage for the recently presented
EXPLORER-HCM (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy) study.

RANDOMIZED, MULTICENTER STUDIES
EXPLORER-HCM is a multicenter, phase 3, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of Mavacamten in treating symptomatic 220 patients with oHCM. EXPLORER-HCM trial enrolled adult patients with an established diagnosis of HCM, maximal LVOT gradient exceeding 50 mm Hg (at rest or provoked by Valsalva maneuver or exercise), preserved left ventricular ejection fraction (LVEF ≥55%), and NYHA class II or III HF symptoms. Moreover, patients had to be capable of performing upright cardiopulmonary exercise testing (CPET). Main exclusion criteria included a history of exercise-induced syncope or sustained ventricular tachyarrhythmia (VT) within 6 preceding months; QT interval corrected using Fridericia's formula >500 ms, AF present on screening electrocardiogram, and any AF without anticoagulation for at least 4 weeks or with insufficient rate control within 6 months before screening. Prior septal reduction therapy did not exclude a patient, provided it was performed more than 6 months before screening. Continuation of standard HCM pharmacotherapy with BB or calcium channel blocker was allowed as long as the dosing remained unchanged for at least 2 weeks before the screening, and no modifications were expected throughout the study. The base dose of mavacamten was 5 mg q.d. and was individually up-titrated to a maximum of 15 mg at weeks 8 and 14 to achieve the target reduction of LVOT gradient <30 mm Hg and mavacamten plasma concentration between 350 ng/ml and 700 ng/ml. The primary composite end-point was defined as an increase of pVO2 by at least 1.5 ml/kg/min accompanied by at least one NYHA class reduction or an increase of pVO2 by at least 3.0 ml/kg/min with no worsening of NYHA class. Among secondary endpoints, changes in post-exercise LVOT gradient, pVO2, percentage of patients with at least one NYHA class improvement, and cardiomyopathy questionnaires (KCCQ-CSS, HCMSQ-SoB) were evaluated.

Eligible adults with oHCM and NYHA were randomized 1:1 to receive once-daily, oral mavacamten, or matching placebo for 30 weeks [30]. 98% of patients enrolled completed the study. Of the 2% who dropped out, none were due to reduced LVEF or symptoms of HF. Overall rates of adverse events, serious adverse events, and cardiac adverse events, including AF, were comparable for patients treated with mavacamten and placebo. Safety and tolerability were similar to placebo. One patient died by sudden death in the placebo group.

Main results
The primary endpoint was achieved by 45 (37%) patients in mavacamten group and 22 (17%) in placebo group (+ 19.4%; 95% CI, 8.7–30.1; \(P = 0.0005\)). Additionally, in the mavacamten group, an increase of pVO\(_2\) by at least 3.0 ml/kg/min together with at least one NYHA class improvement was noted in 45 (37%) patients, while the same effect in the placebo group was found in 10 patients (difference + 12.5%; 95% CI, 4.0–21.0).

Secondary end-points also pointed at the improvement associated with mavacamten administration. The decrease in post-exercise LVOT gradient in the treated group was greater by 35.6 mm Hg (95% CI, −43.2 to −28.1; \(P < 0.0001\)) with a mean reduction from 86 mm Hg to 38 mm Hg vs 84 mm Hg to 73 mm Hg. The pVO\(_2\) increase with mavacamten was 1.4 ml/kg/min greater than with placebo (95% CI, 0.6–2.1; \(P = 0.0006\)). 80 (65%) patients treated with mavacamten noted an improvement by at least one NYHA class vs 40 (31%) patients receiving placebo (difference 33.8%; 95% CI, 22.2–45.4; \(P < 0.0001\)). Furthermore, in the mavacamten group 61 (50%) patients achieved NYHA class I, whereas in the placebo group, there were 27 (21%) of them. Correspondingly, also patient-reported outcomes as assessed by KCCQ-CCS (positive change better) and HCMSQ-SoB (negative change better) favored treatment with mavacamten (KCCQ-CCS +9.1; 95% CI, 5.5–12.7; HCMSQ-SoB −1.8; −2.4 to −1.2; \(P < 0.0001\) for both). Complete response was defined as a reduction of LVOT gradient <30 mm Hg together with achieving NYHA class I. Such a result was noted in 32 (27%) patients treated with mavacamten, and only 1 (1%) receiving placebo (+26.6%; 95% CI, 18.3–34.8). Reduction of LVOT gradient below the standard cut-off value for interventional treatment that is <50 mm Hg was achieved by 53% more often in the mavacamten group (75, 74% vs 22, 21%; 95% CI, 42.0–65.0).

Notably, a significant number of patients on placebo had improvement in the primary end-point and NYHA class. This highlights the need for proper double-blinding in such studies, which evaluate the physical performance and HF symptoms. On the other hand, the reduction of the NT-proBNP observed in the mavacamten group supported the conclusion that the differences between the groups were truly significant. Also, the reduction of the LVOT gradient was by 35% greater on mavacamten than on placebo and all of the secondary end-points were consistently showing the superiority of the drug over placebo. Another important issue is the variability of the LVOT gradients. The variability tends to be higher for resting gradients and less for gradients provoked by exercise. The post-exercise gradient was the secondary end-point of the trial, which makes the variability less relevant.

Reduction of cardiac biomarkers concentration was similarly rapid and sustained, parallel to the hemodynamic changes noted. At week 30 compared with baseline, the drop in NT-proBNP
after mavacamten treatment was 80% greater than for placebo, and the decrease in hs-cTnI was 41% greater for mavacamten than for placebo.

**NONOBSTRUCTIVE HCM**

The 2nd direction of investigation (MAVERICK-HCM study) was designed to evaluate the dosing of mavacamten in HCM without LVOTO since the drug has extended pharmacokinetic properties [31]. 59 patients were enrolled and observed for over 16 weeks. Patients were subdivided into 3 subgroups (n = 19 allocated to serum drug concentration of ~200 ng/ml, n = 21 allocated to ~500 ng/ml, and n = 19 to placebo), followed by an 8-week washout period. The MAVERICK-HCM study fulfilled its primary objective concerning safety and tolerability. The drug was well tolerated, with no differences in reported serious adverse events (SAE) between treatment groups (10% on mavacamten and 21% on placebo). A common SAE was AF (5% in both groups), and the majority of other side effects (>70%) were not clinically relevant. The main secondary outcome was a reduction in plasma biomarkers. In the pooled mavacamten groups, the NT-proBNP decreased by 53% versus 1% in the placebo group (–435 pg/ml vs –6 pg/ml; \( P = 0.0005 \)). Similarly, the cardiac troponin I also decreased by 34% in the pooled-mavacamten group compared to 4% increase in the placebo group (\( P = 0.009 \)).

The investigators evaluated exploratory functional end-points, including peak VO\(_2\) or NYHA functional class. Among a high-risk subgroup with elevated myocardial injury biomarkers (cardiac troponin I >99th percentile) or elevated diastolic filling pressures (average E/e' >14 on Doppler-echocardiogram), one-third of mavacamten treated patients met the composite functional end-point defined as achieving: 1) an improvement of at least 1.5 ml/kg/min in peak VO\(_2\) with a reduction of NYHA functional class; or 2) an improvement of 3.0 ml/kg/min or more in peak VO\(_2\) with no worsening in NYHA functional class — compared with none in the placebo group (\( P = 0.03 \)). The effect on the plasma level of both biomarkers is particularly beneficial in the face of recent evidence of the unfavorable role of the persistently high levels of these biomarkers in HCM [32, 33].

**IMAGING STUDIES**

The recent cardiac magnetic resonance substudy of EXPLORER [34] is the first to show the favorable influence of mavacamten on cardiac remodeling in HCM. Mavacamten was associated with a significant reduction in the total intracellular myocardial mass index as well as LV mass index, maximum LV wall thickness, and left atrial volume index. Importantly, no changes in fibrosis level were observed over 30 weeks. Furthermore, the contractile function
was maintained in the normal range. Reduction in hypertrophy and left atrial volume were demonstrated parallelly with a decrease in plasma level of biomarkers of myocardial stress and injury.

**ONGOING STUDIES**

The findings of EXPLORER-HCM and MAVERICK-HCM studies are further confirmed in two ongoing long-term extension studies — A Long-term Safety Extension Study of Mavacamten (MYK461) in Adults with Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE).

The main goals of LTE are: 1) assessment of the long-term safety and tolerability of mavacamten in participants with HCM who completed the prior studies; 2) data on the long-term outcomes in patients with symptomatic noHCM and oHCM; and 3) to evaluate an echo-guided mavacamten titration algorithm in symptomatic oHCM participants. The active treatment in both studies is 2 years, and all patients receive the drug.

VALOR-HCM (Evaluation of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy who are Eligible for Septal Reduction Therapy) study will verify the hypothesis that in patients (n = 100) with symptomatic oHCM the course of mavacamten over 16 week will reduce the need for SRT [35]. Until then SRT remains the most effective treatment for drug-refractory oHCM [36].

**CLINICAL PERSPECTIVE**

Mavacamten seems to be a useful drug for the full spectrum of HCM presentations (obstructive and nonobstructive). Beneficial effects include LVOT gradient reduction, an increase of exercise tolerance, and a decreased level of biomarkers (reduction wall stress and ischemia injury). Also, clinical status and quality of life tend to follow these hemodynamic changes. Mavacamten is the first in class drug targeting the key underlying molecular mechanisms of cardiomyocyte hypercontractility in HCM.

**REFERENCES**


Figure 1. Mechanism of Mavacamten action